Research programme: ion channel and GABA A modulators - Saniona

Drug Profile

Research programme: ion channel and GABA A modulators - Saniona

Alternative Names: AN 346; AN 363; AN 470; AN 761; AN-726; NS9283; NSD-708; NSD-761; NSD-847; NSD-867; SAN 711

Latest Information Update: 22 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; NeuroSearch
  • Developer Saniona
  • Class Analgesics; Anti-inflammatories; Antipruritics; Neuroprotectants
  • Mechanism of Action Alpha4beta2 nicotinic receptor modulators; Alpha7 nicotinic acetylcholine receptor agonists; GABA A alpha 2 receptor modulators; GABA A alpha 3 receptor modulators; GABA A receptor modulators; GABA modulators; Intermediate conductance calcium activated potassium channel modulators; Ion channel modulators; Small conductance calcium activated potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; CNS disorders; Dyskinesias; Inflammatory bowel diseases; Neuropathic pain; Pruritus; Schizophrenia

Most Recent Events

  • 05 Dec 2017 Development of ion channel and GABA A modulators for CNS disorders, Dyskinesia, Inflammatory bowel disease and Neuropathic pain is ongoing Denmark
  • 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders in Denmark
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Dyskinesia in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top